Trials / Conditions / Scleroderma, Diffuse

Scleroderma, Diffuse

15 registered clinical trials studyying Scleroderma, Diffuse — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis NCT06655896	Novartis Pharmaceuticals	Phase 2
Unknown	ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma NCT05148598	Paracrine, INC.	Phase 3
Completed	Phenotyping of Chronic Pain in Diffused Systemic Scleroderma NCT05622578	Assistance Publique - Hôpitaux de Paris	N/A
Unknown	Novel Splinting Technique Using 3D Models NCT05351060	Giovanna Fichera	N/A
Completed	Effects of FT011 in Systemic Sclerosis NCT04647890	Certa Therapeutics	Phase 2
Terminated	A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients NCT04837131	Michael M. Pham	Phase 2
Completed	Exercise With Scleroderma Functional Outcomes NCT06425653	Trakya University	N/A
Completed	Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis NCT04464434	UMC Utrecht	Phase 4
Completed	Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis NCT03831438	Bristol-Myers Squibb	Phase 1
Active Not Recruiting	Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypert NCT02682511	Cumberland Pharmaceuticals	Phase 2
Completed	Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis NCT02503644	Inventiva Pharma	Phase 2
Terminated	Exparel as a Nerve Block for Severe Hand Pain NCT02374320	Jose Soberon, MD	Phase 2 / Phase 3
Completed	Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis NCT01347008	Federal University of São Paulo	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Sclerode NCT00442611	Stanford University	Phase 1 / Phase 2
Unknown	High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Scleros NCT00428883	Università Politecnica delle Marche	Phase 2 / Phase 3